Does LAROTRECTINIB Cause Neoplasm malignant? 7 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Neoplasm malignant have been filed in association with LAROTRECTINIB (VITRAKVI). This represents 0.9% of all adverse event reports for LAROTRECTINIB.
7
Reports of Neoplasm malignant with LAROTRECTINIB
0.9%
of all LAROTRECTINIB reports
1
Deaths
0
Hospitalizations
How Dangerous Is Neoplasm malignant From LAROTRECTINIB?
Of the 7 reports, 1 (14.3%) resulted in death.
Is Neoplasm malignant Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for LAROTRECTINIB. However, 7 reports have been filed with the FAERS database.
What Other Side Effects Does LAROTRECTINIB Cause?
Fatigue (56)
Drug ineffective (52)
Dizziness (50)
Death (48)
Pain (42)
Neuropathy peripheral (39)
Nausea (32)
Off label use (31)
Disease progression (27)
Malignant neoplasm progression (23)
What Other Drugs Cause Neoplasm malignant?
RANITIDINE (10,648)
ADALIMUMAB (2,028)
APIXABAN (1,772)
ETANERCEPT (1,616)
METHOTREXATE (1,041)
TOFACITINIB (1,020)
RITUXIMAB (929)
INFLIXIMAB (892)
ABATACEPT (727)
RISANKIZUMAB-RZAA (715)
Which LAROTRECTINIB Alternatives Have Lower Neoplasm malignant Risk?
LAROTRECTINIB vs LASILIX
LAROTRECTINIB vs LASIX
LAROTRECTINIB vs LASMIDITAN
LAROTRECTINIB vs LATANOPROST
LAROTRECTINIB vs LATANOPROSTENE BUNOD